๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Squamous Non-Small Cell Lung Cancer
Clinical trial register · China

Non-Squamous Non-Small Cell Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 5 Wuhan 2 Hangzhou 2 Jinan 1 Tianjin 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou5 Wuhan2 Hangzhou2 Jinan1 Tianjin1
All 12 locations
Target enrolment
to

Non-Squamous Non-Small Cell Lung Cancer trials in China

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
NCT07264816Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
80
Wuhan
2026-02-03
Not yet open
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
NCT07383116Non Squamous Non-small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3
500
Shanghai
2026-01-15
Recruiting
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
NCT07178795Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
440
Guangzhou
2025-09-29
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT06417008Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 2/3
1,080
Tianjin, Hangzhou
2024-05-28
Not yet open
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
NCT06335355Non-squamous Non-small Cell Lung Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3
401
Jinan
2024-03
Active, closed
Phase 3 Clinical Study of AK112 for NSCLC Patients
NCT05184712Non-Squamous Non-small Cell Lung Cancer
Akeso
Phase 3
322
Guangzhou
2022-01-25
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/non-squamous-non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies listing the condition Non-Squamous Non-Small Cell Lung Cancer.

How many Non-Squamous Non-Small Cell Lung Cancer trials are recruiting in China?

6 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Squamous Non-Small Cell Lung Cancer), 10 studies
PhaseStudiesRecruitingShare
Phase 2/34240%
Phase 34240%
Phase 22220%

Most active sponsors

Lead sponsors with the most studies (Non-Squamous Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.32
AbbVie11
Akeso10
AstraZeneca11
Hansoh BioMedical R&D Company11
Shanghai Huaota Biopharmaceutical Co., Ltd.10
Shanghai Junshi Bioscience Co., Ltd.11
Shanghai Shengdi Pharmaceutical Co., Ltd10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.